Sara Nayeem
Directeur/Membre du Conseil chez CENTREXION THERAPEUTICS CORPORATION
Profil
Sara Nayeem is currently the Director at Centrexion Therapeutics Corp., the Director at New England Venture Capital Association, Inc., the Director at Cydan LLC, the Director at Tiburio Therapeutics, Inc., and the Executive Vice President & Investments at Enavate Sciences.
Previously, she served as the Independent Director at Mersana Therapeutics, Inc., the Director at Cydan II, Inc., the Director at Biohealth Innovation, Inc., the Director at Vtesse, Inc., the Director at NightstaRx Ltd., the Director at Therachon SAS, the Independent Director at Imara, Inc., the Director at Xperi Corp., the Director at Therachon AG, the Director at Complexa, Inc., the Investment Banking Analyst at Morgan Stanley & Co. LLC, the Partner at NEA Management Co. LLC, the Associate at Merrill Lynch Global Private Equity, Inc., the Associate at Merrill Lynch & Co., Inc., the Partner at New Enterprise Associates LLC, and the Partner at Avoro Ventures LLC.
She obtained her undergraduate degree from Harvard University and holds an MBA and a doctorate from Yale University.
Postes actifs de Sara Nayeem
| Sociétés | Poste | Début |
|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Directeur/Membre du Conseil | 01/01/2018 |
Cydan LLC
 Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
New England Venture Capital Association, Inc.
 New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Tiburio Therapeutics, Inc.
 Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Enavate Sciences
 Enavate Sciences Financial ConglomeratesFinance Enavate Sciences is a platform created by Patient Square Capital to support therapeutic companies in advancing medicines and enabling technologies to address patient needs. The company is based in Delaware. Enavate strives to empower a diverse portfolio of therapeutic companies to accelerate innovation through capital support and operational experience. James P. Boylan has been the CEO of the American company since 2022. | President | 01/12/2023 |
Anciens postes connus de Sara Nayeem
| Sociétés | Poste | Fin |
|---|---|---|
Avoro Ventures LLC
 Avoro Ventures LLC Investment ManagersFinance Avoro Ventures LLC (Avoro Ventures) is a venture capital subsidiary of Avoro Capital Advisor LLC founded in 2020. The firm is headquartered in New York. | Private Equity Investor | 31/10/2023 |
| IMARA | Directeur/Membre du Conseil | 15/11/2021 |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Private Equity Investor | 01/02/2021 |
New Enterprise Associates LLC
 New Enterprise Associates LLC Investment ManagersFinance New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich. | Corporate Officer/Principal | 01/02/2021 |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Sara Nayeem
| Yale University | Doctorate Degree |
| Harvard University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 20 |
|---|---|
NEA Management Co. LLC
NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Finance |
Merrill Lynch Global Private Equity, Inc.
 Merrill Lynch Global Private Equity, Inc. Investment ManagersFinance Headquartered in New York City, Merrill Lynch Global Partners (MLGP), formerly Merrill Lynch Private Equity Group, is the private equity investment arm of Merrill Lynch & Co., Inc. (NYSE: MER) | Finance |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
Cydan II, Inc.
 Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Health Technology |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Health Technology |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
Biohealth Innovation, Inc.
 Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Finance |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
New Enterprise Associates LLC
New Enterprise Associates LLC Investment ManagersFinance New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich. | Finance |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Health Technology |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | Commercial Services |
Avoro Ventures LLC
Avoro Ventures LLC Investment ManagersFinance Avoro Ventures LLC (Avoro Ventures) is a venture capital subsidiary of Avoro Capital Advisor LLC founded in 2020. The firm is headquartered in New York. | Finance |
| Merrill Lynch & Co., Inc. | Finance |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Distribution Services |
Xperi Corp.
 Xperi Corp. SemiconductorsElectronic Technology Xperi Corp. engages in creating, developing and licensing audio, imaging, semiconductor packaging and interconnect technologies. It operates through the following two segments: Product Licensing and Semiconductor & IP Licensing. The Product Licensing segment comprises of audio and imaging businesses, which licenses through the DTS, FotoNation, HD Radio, and IMAX Enhanced brands. The Semiconductor & IP Licensing segment licenses semiconductor packaging and interconnects technologies and associated intellectual property. The company was founded in 1990 and is headquartered in San Jose, CA. | Electronic Technology |
| Therachon AG | |
Enavate Sciences
Enavate Sciences Financial ConglomeratesFinance Enavate Sciences is a platform created by Patient Square Capital to support therapeutic companies in advancing medicines and enabling technologies to address patient needs. The company is based in Delaware. Enavate strives to empower a diverse portfolio of therapeutic companies to accelerate innovation through capital support and operational experience. James P. Boylan has been the CEO of the American company since 2022. | Finance |
